Pulse Biosciences (PLSE) Net Cash Flow (2015 - 2025)

Pulse Biosciences' Net Cash Flow history runs 11 years deep, the most recent figure standing at -$14.5 million for Q4 2025.

• On a quarterly basis, Net Cash Flow fell 137.12% year-over-year to -$14.5 million in Q4 2025; TTM through Dec 2025 was -$37.3 million, a 150.63% decrease from a year earlier, with the FY2025 full-year figure at -$37.3 million, down 150.63% from the prior year.
• Net Cash Flow retreated to -$14.5 million in Q4 2025 per PLSE's latest filing, from -$11.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $54.4 million in Q3 2022 and bottomed at -$15.9 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$7.5 million (2022), against an average of $3.4 million.
• Biggest YoY gain for Net Cash Flow was 4813.99% in 2021; the steepest drop was 348.04% in 2021.
• Year by year, Net Cash Flow stood at -$13.4 million in 2021, then surged by 40.02% to -$8.0 million in 2022, then increased by 24.95% to -$6.0 million in 2023, then jumped by 747.82% to $39.0 million in 2024, then sank by 137.12% to -$14.5 million in 2025.
• Per Business Quant, the three latest PLSE Net Cash Flow figures stand at -$14.5 million (Q4 2025), -$11.1 million (Q3 2025), and -$12.9 million (Q2 2025).